2 secret growth stocks that could make you a fortune

Royston Wild looks at two shares with hot earnings potential.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It surprises me not in the slightest that Kainos Group (LSE: KNOS) was marching to fresh record highs above 300p per share on Monday.

The software specialist has the wind in its sales with demand from both new and existing customers continuing to boom, and this was illustrated in half-year trading details released today.

Kainos declared that revenues increased 2% during the six months to September, to £41.4m, a result that pushed adjusted pre-tax profit 1% higher to £7.1m. What really grabbed the eye, however, was news of a demand surge for its ‘Software as a Service’ (or SaaS) bookings which shot to £5.3m from £1.5m.

And in a promising sign for future revenues, the Belfast-based firm said that sales orders almost doubled year-on-year, to £63.4m from £32.6m in the corresponding 2016 period, while its sales backlog leapt to £97.1m, up 43%.

Continental march continues

These interim results underline the exceptional progress Kainos is making both at home and abroad.

In Europe the business boosted the number of clients on its books in the first half to 17 from nine in the same period last year, and Kainos now sources 26% of total sales from international clients versus 19% previously. And the company opened new offices in Frankfurt and Copenhagen (on top of new premises in Birmingham) in the first half in a bold statement of intent.

Tech stocks with stonking momentum often carry a premium and Kainos is no exception. With City analysts predicting a 5% earnings rise in the 12 months ending March 2018 the business sports a forward P/E ratio of 29.8 times.

But I consider this to be a price worth paying given the scope for explosive profits growth later on (indeed, current forecasts points towards a 21% earnings explosion in fiscal 2019 alone).

Meanwhile, the company is also highly cash-generative (the amount of cash on the balance sheet swelled by almost a third in the first half, to £27.3m), providing it with plenty of ammunition to deliver its exciting growth plans.

The drugs DO work

Alliance Pharma (LSE: APH) is another share tipped by the City to enjoy improving earnings momentum beyond the current period.

During 2017, the medicines dispenser is anticipated to report a 2% earnings rise, and to follow this up with a 13% advance next year.

These bubbly predictions come as no surprise as the Chippenham company, much like Kainos, makes impressive progress in international markets.

Alliance Pharma advised in September that, as sales at its Kelo-cote and MacuShield brands jumped 52% and 67% during January-June, group revenues advanced 8% to £50.3m. It said that demand for these products jumped thanks to “a combination of distribution gains in new territories and growth in the rates of sale in existing outlets, stimulated by our increased marketing investment.”

And the business has plenty of financial firepower to keep pushing organic investment, not to mention embark on further exciting bolt-on acquisitions like that of Sinclair Pharma made back in 2015 (cash and cash equivalents jumped £1.8m during the first six months of 2017 to £9m).

These factors, allied to the defensive nature of the pharmaceuticals sector, makes Alliance Pharma a seriously good pick for growth hunters in my opinion. And an extrememly-cheap forward P/E multiple of 15.1 times seals the deal.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

5 steps to start buying shares with under £500

Learn how this writer would start buying shares with a few hundred pounds in a handful of steps, if he…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

The FTSE 100 offers some great bargains. Is this one?

Our writer digs into one FTSE 100 share that has had a rough 2024 to date, ahead of its interim…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »